Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022

Published: Apr, 2018 | Pages: 230 | Publisher: RNCOS
Industry: Healthcare | Report Format: Electronic (PDF)

The global immune-oncology market is anticipated to rise at a significant CAGR in the forecast period. Immune-oncology market is driven by factors such as manufacturers’ emphasis on upgrading immune-oncology drugs as well as increase in R&D to develop anti-cancer drugs. Development of innovative products coupled with product launches is anticipated to propel market growth in the near future. Increasing advances in healthcare settings and use of innovation in medical sector are now emphasizing better services to offer to cancer patients, which in turn has bolstered the immune-oncology market.

By Type, the immune-oncology market segmentation includes mAb (Naked, Conjugate), Cancer Vaccines and Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4). By Application, the immune-oncology market is segmented as Lung, Melanoma, Leukemia, and Lymphoma. Leukemia and lymphoma account for a higher market due to rise in prevalence and low medical attention. Lung diseases witnessed a remarkable CAGR due to rise pollution and change in lifestyle.

Geographical segmentation for immune-oncology market includes North America, Latin America, Europe, Middle East, Asia-Pacific and Middle East and Africa. North America dominates the market growth in the global scenario owing to rise in improvements in healthcare settings and improved medical care. Advances in medicines and mode of drug administration also propels the growth of U.S. market. European market is expected to follow the same trend with a slight difference of reimbursement scenario. Favorable reimbursement for medical and cancer cases fuels the market.

Asia-Pacific regions account for a significant market share in the global scenario rise in cancer patients and favorable reimbursements. Prominent players in the immune-oncology market include Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Pfizer Inc., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Eli Lilly and Company, Merck & Co., Prometheus Therapeutics & Diagnostics, Sanofi S.A., EMD Serono, Inc., Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, Gilead Sciences Inc. and Incyte.

Immuno-oncology is a unique approach that uses the body’s immune system to fight cancer. These therapies activate an individual’s immune system, making it able to recognize cancer cells and destroy them. Immuno-oncology therapies provide long lasting anti-cancer benefits to patients who previously had very few treatment options available to them. These therapies work against a large number of cancer types. The technological advancements are helping the growth of immuno-oncology market. The biotechnology and pharmaceutical companies are striving to launch new and most effective therapies.

According to the report “Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022”, the global immuno-oncology market is anticipated to cross US$ 100 Billion by 2022. The report provides a detailed analysis of the global immuno-oncology market. The report also provides the current and forecasted market for immuno-oncology.

Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immuno-oncology market. Moreover, the report provides the sales of major marketed immuno-oncology drugs.

The global immuno-oncology market has been segmented on the basis of type of product into monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2016 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme pro-drug therapy and radio immunotherapy).

The report also sheds light on the geographic segmentation of the global immuno-oncology market. In 2016, North America was estimated to account for the largest share. Presence of major players, increased awareness and better distribution mechanisms are some of the prominent factors that have led to North America being the market leader.

On the basis of type of cancer, the immuno-oncology market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2022.

A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immuno-oncology programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.

The later part of the report discusses some of the prominent players in the global immuno-oncology market. Market share analysis of major players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immuno-oncology is an important and rapidly emerging field. This report will prove as a complete source of knowledge and analysis for clients and potential investors.

 Table of Content

1. Analyst View

2. Research Methodology

3. Immuno-Oncology: Overview

4. Market Dynamic
    4.1 Drivers
          4.1.1 Increasing Cancer Incidences
          4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
          4.1.3 Growing Geriatric Population
          4.1.4 High Healthcare Spending in Developed Economies
          4.1.5 Strong Pipeline
          4.1.6 Increasing Efficacy in a Wide Variety of Indications
          4.1.7 urgeoning Approval and Uptake of Immuno-Oncology Products
    4.2 Challenges
          4.2.1 Patent Expiry of Top-Selling Drugs
          4.2.2 Increasing Number of Side-Effects Post Immunotherapy Treatment
          4.2.3 Sky-High Development Costs of Cancer Immunotherapies
          4.2.4 High Cost of Treatment
          4.2.5 Lack of Awarenes
    4.3 Opportunities
          4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunit
          4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival
          4.3.3 CAR-T Therapies: The Future of Cancer Care
          4.3.4 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies

5. Global Immuno-Oncology Market Outlook 2022

6. Global Immuno-Oncology Market, by Product Class
    6.1 Monoclonal Antibodies (mAbs)
          6.1.1 Naked Monoclonal Antibodies
                   6.1.1.1 Rituxan (Rituximab)
                   6.1.1.2 Avastin (Bevacizumab)
                   6.1.1.3 Herceptin (Trastuzumab)
          6.1.2 Conjugated Monoclonal Antibodies
                   6.1.2.1 ADCETRIS (Brentuximab vedotin)
                   6.1.2.2 Kadcyla (Ado-trastuzumab emtansine/TDM-1)
          6.1.3 Bispecific Monoclonal Antibodies
                   6.1.3.1 Blincyto (Blinatumomab)
          6.1.4 Others
    6.2 Therapeutic Vaccines
          6.2.1 Provenge
    6.3 Immune Checkpoint Inhibitors
          6.3.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
                   6.3.1.1 Yervoy (Ipilimumab)
          6.3.2 PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death   Ligand
                   6.3.2.1 Opdivo (Nivolumab)
                   6.3.2.2 Keytruda (Pembrolizumab)
    6.4 Others

7. Global Immuno-Oncology Market, By Major Indications
    7.1 Head & Neck Cancer
    7.2 Lung Cancer
    7.3 Melanoma
    7.4 Lymphoma
    7.5 Leukemia
    7.6 Others 118

8. Global Immuno-Oncology Market, By Geography
    8.1 North America
    8.2 Europe
    8.3 Asia-Pacific

9. Trends & Developments
    9.1 Lucrative Investment Trend
    9.2 Emergence of Targeted and Combination Therapies
    9.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market
    9.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers

10. Strategic Collaborations & Alliances in the Immuno-Oncology Industry

11. Pipeline Analysis of Immuno-Oncology

12. Competitive Landscape
      12.1 Share of Major Players

13. Key Players Analysis
      13.1 F. Hoffmann-La Roche AG
      13.2 Celgene Corporation
      13.3 Bristol-Myers Squibb
      13.4 Merck & Co., Inc.
      13.5 Novartis
      13.6 AstraZeneca Plc
      13.7 Pfizer Inc
      13.8 Eli Lilly and Company
      13.9 Johnson & Johnson
      13.10 Amgen Inc.

List of Tables:

Table 4-1: Immuno-Oncology - Late Stage Research Pipeline
Table 4-2: US & Europe - Major Drug Patent Expiry in Immuno-Oncology Market
Table 6-1: Ongoing Trials for Rituxan 
Table 6-2: Ongoing Trials for Avastin 
Table 6-3: Ongoing Trials for Herceptin 
Table 6-4: Ongoing Trials for ADCETRIS 
Table 6-5: Ongoing Trials for Kadcyla 
Table 6-6: Ongoing Trials for Blincyto 
Table 6-7: Ongoing Trials for Other Monoclonal Antibodies 
Table 6-8: Ongoing Trials for Provenge 
Table 6-9: Ongoing Trials for Yervoy 
Table 6-10: Ongoing Trials for Opdivo 
Table 6-11: Ongoing Trials for Keytruda 
Table 6-12: Ongoing Trials for Other Immuno-Oncology Products 
Table 7-1: Global - Oncology Incidence by Geography (‘000), 2015 & 2020 
Table 9-1: Immuno-Oncology Companies that Received Venture Capital Investments 
Table 9-2: Selected Immuno-Oncology and/or Targeted Therapy Combinations 
Table 10-1: Strategic Collaborations in the Immuno-Oncology Industry 
Table 11-1: Active Immuno-Oncology Programs 
Table 11-2: Global – Immuno-Oncology Product Pipeline 
Table 13-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), 2014-2016 
Table 13-2: F. Hoffmann-La Roche AG - Commercialized Immuno-Oncology Products 
Table 13-3: F. Hoffmann-La Roche AG - Product Pipeline 
Table 13-4: Celgene Corporation - Key Financials (Million US$), 2014-2016 
Table 13-5: Celgene Corporation - Commercialized Immuno-Oncology Products 
Table 13-6: Celgene Corporation - Product Pipeline 
Table 13-7: Bristol Myers Squibb - Key Financials (Million US$), 2014-2016 
Table 13-8: Bristol Myers Squibb - Commercialized Immuno-Oncology Products 
Table 13-9: Bristol Myers Squibb - Product Pipeline 
Table 13-10: Merck & Co., Inc. - Key Financials (Million US$), 2014-2016 
Table 13-11: Merck & Co., Inc. - Commercialized Immuno-Oncology Products 
Table 13-12: Merck & Co., Inc. - Product Pipeline 
Table 13-13: Novartis - Key Financials (Billion US$), 2014-2016
Table 13-14: Novartis - Commercialized Immuno-Oncology Products
Table 13-15: Novartis - Product Pipeline
Table 13-16: AstraZeneca Plc - Key Financials (Million US$), 2014-2016
Table 13-17: AstraZeneca Plc - Commercialized Immuno-Oncology Products
Table 13-18: AstraZeneca Plc - Product Pipeline
Table 13-19: Pfizer Inc - Key Financials (Billion US$), 2014-2016
Table 13-20: Pfizer Inc - Commercialized Immuno-Oncology Products
Table 13-21: Pfizer Inc - Product Pipeline
Table 13-22: Eli Lilly and Company - Key Financials (Million US$), 2014-2016
Table 13-23: Eli Lilly and Company - Commercialized Immuno-Oncology Products
Table 13-24: Eli Lilly and Company - Product Pipeline
Table 13-25: Johnson & Johnson - Key Financials (Billion US$), 2014-2016
Table 13-26: Johnson & Johnson - Commercialized Immuno-Oncology Products
Table 13-27: Johnson & Johnson - Product Pipeline
Table 13-28: Amgen Inc. - Key Financials (Billion US$), 2014-2016
Table 13-29: Amgen Inc. - Commercialized Immuno-Oncology Products
Table 13-30: Amgen Inc. - Product Pipeline

List of Figures:

Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
Figure 4-3: Global - Population above 60 Years (Billion), 2015 & 2050
Figure 4-4: Expected Combination Regimen Launches in Oncology
Figure 5-1: Global - Immuno-Oncology Market (Billion US$), 2016-2022
Figure 6-1: Global - Share of Immuno-Oncology Market by Product (%), 2016
Figure 6-2: Global - Share of Immuno-Oncology Market by Product (%), 2022
Figure 6-3: Global - Monoclonal Antibodies Market (Billion US$), 2016-2022
Figure 6-4: Global - Rituxan Market (Billion US$), 2012-2016
Figure 6-5: Global - Avastin Market (Billion US$), 2012-2016
Figure 6-6: Global - Herceptin Market (Billion US$), 2012-2016
Figure 6-7: Global - ADCETRIS Market (Million US$), 2012-2016
Figure 6-8: Global - Kadcyla Market (Million US$), 2013-2016 
Figure 6-9: Global - Blincyto Market (Million US$), 2014-2016
Figure 6-10: Global - Other Monoclonal Antibodies Market (Billion US$), 2016-2022
Figure 6-11: Global - Therapeutic Cancer Vaccines Market (Billion US$), 2016-2022
Figure 6-12: Global - Provenge Market (Million US$), 2012-2016 
Figure 6-13: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2016-2022 
Figure 6-14: Global - Yervoy Market (Million US$), 2012-2016 
Figure 6-15: Global - Opdivo Market (Million US$), 2014-2016 
Figure 6-16: Global - Keytruda Market (Million US$), 2014-2016 
Figure 6-17: Global - Others Market (Billion US$), 2016-2022
Figure 7-1: Global - Share of Immuno-Oncology Market by Application (%), 2016
Figure 7-2: Global - Share of Immuno-Oncology Market by Application (%), 2022 
Figure 7-3: Global - Head & Neck Cancer Market (Billion US$), 2016-2022 
Figure 7-4: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016 
Figure 7-5: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016 
Figure 7-6: Global - Lung Cancer Market (Billion US$), 2016-2022 
Figure 7-7: Lung Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-8: Lung Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016 
Figure 7-9: Global - Melanoma Market (Billion US$), 2016-2022
Figure 7-10: Melanoma - Immunotherapy Pipeline Analysis by Product (%), 2016 
Figure 7-11: Melanoma - Immunotherapy Pipeline Analysis by Phase (%), 2016 
Figure 7-12: Global - Lymphoma Market (Billion US$), 2016-2022 
Figure 7-13: Lymphoma - Immunotherapy Pipeline Analysis by Product (%), 2016 
Figure 7-14: Lymphoma - Immunotherapy Pipeline Analysis by Phase (%), 2016 
Figure 7-15: Global - Leukemia Market (Billion US$), 2016-2022 
Figure 7-16: Leukemia - Immunotherapy Pipeline Analysis by Product (%), 2016 
Figure 7-17: Leukemia - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-18: Global - Other Cancer Market (Billion US$), 2016-2022 
Figure 7-19: Other Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016 
Figure 7-20: Other Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016 
Figure 8-1: Global - Share of Immuno-Oncology Market by Geographic Regions (%), 2016 
Figure 8-2: Global - Share of Immuno-Oncology Market by Geographic Regions (%), 2022 
Figure 8-3: North America - Immuno-Oncology Market (Billion US$), 2016-2022 
Figure 8-4: Europe - Immuno-Oncology Market (Billion US$), 2016-2022 
Figure 8-5: Asia-Pacific - Immuno-Oncology Market (Billion US$), 2016-2022 
Figure 9-1: Immuno-Oncology Funding by Product Type (Billion, US$), 2015-2016 
Figure 9-2: Major Investors in Immuno-Oncology Market (2015-2016) 
Figure 9-3: Bristol-Myers Squibb and Merck & Co. - Strategic Collaborations 
Figure 11-1: Global - Immuno-Oncology Pipeline Analysis by Product Type (%), 2016 
Figure 11-2: Global - Immuno-Oncology Pipeline Analysis by Phase (%), 2016 
Figure 12-1: Global - Share of Key Players in Immuno-Oncology Market (%), 2015 
Figure 13-1: F. Hoffmann-La Roche AG - Sales by Business Segments (%), 2016 
Figure 13-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Segments (%), 2016 
Figure 13-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Geography (%), 2016 
Figure 13-4: Celgene Corporation - Sales by Products (%), 2016 
Figure 13-5: Bristol Myers Squibb - Revenue by Business Segments (%), 2016 
Figure 13-6: Bristol Myers Squibb - Revenue by Geography (%), 2016 
Figure 13-7: Merck & Co., Inc. - Revenue by Business Segments (%), 2016 
Figure 13-8: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segments (%), 2016 
Figure 13-9: Merck & Co., Inc. - Revenue by Geography (%), 2016 
Figure 13-10: Novartis - Sales by Business Segments (%), 2016 
Figure 13-11: Novartis - Innovative Medicines Division Sales by Segments (%), 2016 
Figure 13-12: Novartis - Pharmaceuticals Division Sales by Segments (%), 2016 
Figure 13-13: Novartis - Sales by Geography (%), 2016 
Figure 13-14: AstraZeneca Plc - Revenue by Business Segments (%), 2016 
Figure 13-15: AstraZeneca Plc - Revenue by Geography (%), 2016
Figure 13-16: Pfizer Inc - Revenue by Business Segments (%), 2016 
Figure 13-17: Pfizer Inc - Revenue by Geography (%), 2016 
Figure 13-18: Eli Lilly and Company - Revenue by Business Segments (%), 2016 
Figure 13-19: Eli Lilly and Company - Human Pharmaceutical Division Revenue by Business Segments (%), 2016
Figure 13-20: Eli Lilly and Company - Revenue by Geography (%), 2016
Figure 13-21: Johnson & Johnson - Sales by Business Segments (%), 2016
Figure 13-22: Johnson & Johnson - Sales by Pharmaceutical Segments (%), 2016
Figure 13-23: Johnson & Johnson - Sales by Geography (%), 2016
Figure 13-24: Amgen Inc. - Sales by Product (%), 2016
Figure 13-25: Amgen Inc. - Sales by Geography (%), 2016